Shares of Response Genetics Inc. jumped 18 percent on Thursday after the cancer diagnostic test company signed agreements with six additional health plans and two large health care groups.

The East Los Angeles company’s testing services help determine a patient’s response to certain cancer treatments. Response Genetics said the deals were with Blue Cross/Blue Shield plans in Arizona, Iowa, South Dakota, Pennsylvania, Delaware and West Virginia.

Response Genetics also signed agreements with an unnamed independent physician association covering two states in the Northwestern United States and a commercial health plan covering two states in the Northeastern United States.

Shares closed up 22 cents to $1.42 on the Nasdaq.